ArticleBMC oral health2025
Salivary mitofusin levels in periodontal disease: a cross-sectional case-control study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06510608 (Evaluation of the Roles of Salivary Mitofusin-1 and Mitofusin-2 Levels in Periodontal Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Roles of Salivary Mitofusin-1 and Mitofusin-2 Levels in Periodontal Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitofusin (Mfn) is a mitochondrial fusion protein. It has two isoforms (Mfn1 and 2) and is critical in intracellular energy production, calcium transfer, and phospholipid metabolism. Based on previous evidence linking mitochondrial function with the pathophysiology of periodontal inflammation, we hypothesized that salivary Mfn1 and Mfn2 levels may differ across periodontal health, gingivitis, and periodontitis, and that these levels correlate with markers of inflammatory and oxidative stress. Although previous studies have suggested that Mfn2 plays a role in inflammatory and oxidative pathways, clinical evidence regarding its role in periodontal disease is lacking. The null hypothesis of this study was that salivary Mfn levels are not significantly altered with periodontal conditions and are not correlated with inflammation or oxidative stress markers in saliva.
methodsA total of 81 participants were included in this cross-sectional case-control study, with 27 individuals per group. Periodontally healthy patients, patients with gingivitis, and patients with stage 3 or stage 4 grade C periodontitis were recruited for the study. Mfn-1 and Mfn-2 levels were measured. To identify their correlation with inflammatory mechanisms, interleukin-1β levels, total oxidative status (TOS), and total antioxidant status (TAS) were determined using enzyme-linked immunosorbent assay and colorimetric measurements. The oxidative stress index (OSİ) was calculated.
resultsSalivary Mfn1 levels were significantly higher in patients with periodontitis compared to healthy controls (36.54 ± 13.15 ng/mL, 24.67 ± 8.69 ng/mL, p < 0.001). No significant difference was observed between the groups in terms of Mfn2 levels (p > 0.05). While significant differences were found between Group P and Group H in TAS and OSI values (p < 0.05), TOS values did not show any significant difference between the groups (p > 0.05). A positive correlation was found between Mfn1 and Mfn2 and IL-1β levels (p < 0.05). Mfn1 and Mfn2 did not have any significant correlation with TAS, TOS, or OSI values (p > 0.05).
conclusionsElevated Mfn1 levels in the saliva of patients with periodontitis suggested that mitochondrial function was disrupted in severe periodontitis. Mitofusin levels showed no significant correlation with oxidative stress markers in this study.
trial registrationThis study was registered in ClinicalTrials.gov under the number NCT06510608 on July 18, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.